RAPT Therapeutics (NASDAQ:RAPT) is a U.S.-based medical stage bio-pharma firm working in oncology a
RAPT Therapeutics (NASDAQ:RAPT) is a U.S.-based medical stage bio-pharma firm working in oncology and irritation therapies. The corporate, which went public in October 2019, noticed its inventory rally ~30% in the beginning of the month after it introduced a collaboration settlement with South Korea-based Hanmi Prescription drugs for FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in growth for the remedy of a number of cancers. Beneath this settlement, RAPT would obtain $10 million in an upfront cost and near-term milestone cost. Moreover, RAPT may doubtlessly obtain as much as $48 million in success-based growth milestones and as much as $60 million in potential gross sales milestones, in addition to double-digit royalties on any future gross sales.
Nonetheless, the inventory value corrected over subsequent days. Additionally, when RAPT reported its Q3 outcomes earlier this week, a higher-than-expected loss for the interval triggered a sell-off – sending its inventory right down to the identical stage it was in the beginning of the month.
We step again from these latest swings to evaluation Rapt Therapeutics efficiency over the previous few years, as a context for what would possibly…